

**G.P. KAPADIA & CO**

Chartered Accountants

*Hamam House  
Ambalal Doshi Marg,  
Mumbai - 400 001*Tel. : 2265 4239, 2265 4313  
E-mail : gpkco@yahoo.com

Limited Review Report on the Unaudited Consolidated Financial Results of Unihealth Consultancy Limited for the half year ended September 30,2023 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended).

**To,  
The Board of Directors  
Unihealth Consultancy Limited**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Unihealth Consultancy Limited** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the half year ended September 30, 2023 and the Statement of Assets and Liabilities as on date together with notes thereon and Cash flow statement (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulation, 2015"). The Statement is the responsibility of the Holding Company's management and has been approved by the board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard. requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

## G.P KAPADIA & CO.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities :

Sr. No.	Name	Relationship
1	Unihealth Pharmaceuticals Private Ltd	Subsidiary
2	Aryavarta FZE	Subsidiary
3	Unihealth Tanzania Limited	Subsidiary
4	Biohealth Limited	Subsidiary
5	Victoria Hospital Limited	Joint venture
6	UMC Global Health Limited	Joint venture
7	UHS Oncology Private Limited	Associate
8	Unihealth Uganda Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 2 above, nothing has come to our attention that causes us to believe that the Statement has been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, and has disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries and Joint Ventures included in the consolidated unaudited financial results, whose interim financial results reflect audited total assets of Rs 5134.20 lakhs and cash inflows of Rs (18.49) lakhs as at 30th September 2023, audited total revenue from operations of Rs 2058.50 lakhs for the period ended 30 September 2023, as considered in the consolidated unaudited financial results. These financial results have been audited by other auditors and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this Subsidiary companies, Joint Ventures and associate is based solely on the financial result of the subsidiary as referred aforesaid. Our conclusion on the Statement is not modified in respect of the above matter
7. We did not review the interim financial results of subsidiaries and Joint Ventures included in the consolidated unaudited financial results, whose interim financial results reflect audited total assets of Rs 478.22 lakhs and cash inflows of Rs (41.37) lakhs as at 30th September 2023, audited total revenue from operations of Rs 107.43 lakhs for the period ended 30 September 2023 and loss from associates of Rs 4.39 lakhs, as considered in the consolidated unaudited financial results. These financial results have been prepared by the management and provided to us duly certified and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this Subsidiary

**G.P KAPADIA & CO.**

companies, Joint Ventures and associate is based solely on the financial result of the subsidiary as referred aforesaid. Our conclusion on the Statement is not modified in respect of the above matter

**For G.P Kapadia & Co.  
(Chartered Accountants)**

**FRN No.: 104768W**

**ATUL**

**BABUBHAI**

**DESAI**

**Atul Desai**

**(Partner)**

**Membership No. 030547**

**Place: Mumbai**

**Date: 08<sup>th</sup> November 2023**

**UDIN: 23030850BGRKPD2177**

Digitally signed by ATUL BABUBHAI DESAI  
DN: c=IN, ou=Partners, o=ICAI, email=atul@kapadia.co.in, serial=104768W  
2.5.4.30=6d123818-065c219088761914  
2.5.4.43=6d123818-065c219088761914  
2.5.4.42=6d123818-065c219088761914  
2.5.4.41=6d123818-065c219088761914  
2.5.4.40=6d123818-065c219088761914  
2.5.4.39=6d123818-065c219088761914  
2.5.4.38=6d123818-065c219088761914  
2.5.4.37=6d123818-065c219088761914  
2.5.4.36=6d123818-065c219088761914  
2.5.4.35=6d123818-065c219088761914  
2.5.4.34=6d123818-065c219088761914  
2.5.4.33=6d123818-065c219088761914  
2.5.4.32=6d123818-065c219088761914  
2.5.4.31=6d123818-065c219088761914  
2.5.4.30=6d123818-065c219088761914  
2.5.4.29=6d123818-065c219088761914  
2.5.4.28=6d123818-065c219088761914  
2.5.4.27=6d123818-065c219088761914  
2.5.4.26=6d123818-065c219088761914  
2.5.4.25=6d123818-065c219088761914  
2.5.4.24=6d123818-065c219088761914  
2.5.4.23=6d123818-065c219088761914  
2.5.4.22=6d123818-065c219088761914  
2.5.4.21=6d123818-065c219088761914  
2.5.4.20=6d123818-065c219088761914  
2.5.4.19=6d123818-065c219088761914  
2.5.4.18=6d123818-065c219088761914  
2.5.4.17=6d123818-065c219088761914  
2.5.4.16=6d123818-065c219088761914  
2.5.4.15=6d123818-065c219088761914  
2.5.4.14=6d123818-065c219088761914  
2.5.4.13=6d123818-065c219088761914  
2.5.4.12=6d123818-065c219088761914  
2.5.4.11=6d123818-065c219088761914  
2.5.4.10=6d123818-065c219088761914  
2.5.4.9=6d123818-065c219088761914  
2.5.4.8=6d123818-065c219088761914  
2.5.4.7=6d123818-065c219088761914  
2.5.4.6=6d123818-065c219088761914  
2.5.4.5=6d123818-065c219088761914  
2.5.4.4=6d123818-065c219088761914  
2.5.4.3=6d123818-065c219088761914  
2.5.4.2=6d123818-065c219088761914  
2.5.4.1=6d123818-065c219088761914  
2.5.4.0=6d123818-065c219088761914

**UNIHEALTH CONSULTANCY LIMITED**  
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)  
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034  
CIN : U85100MH2010PLC200491

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2023**


(₹ in Lakhs)

	PARTICULARS	For the Half	For the Year	For the Year
		Year Ended	Ended	Ended
		30.09.2023	31.03.2023	31.03.2022
		Unaudited	Audited	Audited
I	Revenue from operations	2,210.38	4,393.86	3,683.21
II	Other income	74.91	209.15	109.48
III	<b>Total revenue (I + II)</b>	<b>2,285.29</b>	<b>4,603.01</b>	<b>3,792.69</b>
IV	Expenses			
	Cost of materials consumed	-	-	-
	Purchases of stock in trade	484.02	700.41	871.60
	Changes in inventories of Finished goods, Work in progress and Stock-in-trade	(13.83)	27.82	(33.26)
	Employee benefits expense	360.72	647.73	585.98
	Finance costs	153.49	412.13	518.51
	Depreciation and amortization expense	114.16	251.62	221.23
	Other expenses	669.92	1,635.52	1,108.28
V	<b>Total Expense (IV)</b>	<b>1,768.48</b>	<b>3,675.23</b>	<b>3,272.34</b>
VI	<b>Profit/Loss before exceptional and extra-ordinary items and Tax (III - V)</b>	<b>516.81</b>	<b>927.78</b>	<b>520.35</b>
VII	Exceptional Items	-	-	-
VIII	<b>Profit/Loss before extra-ordinary items and Tax</b>			
IX	Tax expense			
	(1) Current tax	105.54	206.70	77.39
	(2) Deferred tax	(18.48)	(44.59)	63.71
X	<b>Profit for the year (VIII - IX) (before Minority interest and profit / (loss) from associates)</b>	<b>429.76</b>	<b>765.67</b>	<b>379.25</b>
	Less: Minority Interest - Share of Profit/(Loss)	1.04	(2.09)	(10.33)
	Add: Share of Profit or loss from Associate co (After Tax)	(4.39)	0.24	(7.56)
XI	<b>Profit / (loss) for the Year</b>	<b>424.32</b>	<b>768.00</b>	<b>382.02</b>
XII	Earnings per equity share:			
	(a) Basic	3.15	6.91	28.47
	(b) Diluted	3.15	6.91	28.47
XIII	Debt Equity Ratio	0.36	1.45	2.59
XIV	Debt Service Coverage Ratio	0.40	0.74	0.65
XV	Interest Service Coverage Ratio	4.37	3.25	2.00

**NOTES :**

- As per MCA Notification dated 16th February 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND AS. As the Company is covered under the exempted category, it has not adopted IND AS for the preparation of financial results.
- The disclosure of comparative figures for half year ended 30th September 2022 and half year ended 31st March 2023 as per the requirement of SEBI (LODR) Regulations 2015 is not applicable as the company was listed on NSE SME platform on 21/09/2023
- The Statutory Auditors of the Company have carried out review of the financial results for the Half Year ended on September 30, 2023 in compliance with terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The above financial results have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held 08th November, 2023.
- Figures for the previous periods /year have been regrouped ,restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation.
- The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company.
- The company has issued and allotted 42,84,000 equity shares of Rs.10 each at a premium of Rs.122 per share on 21/09/2023 through initial public offer as per section 52 of companies act, 2013, aggregating to Rs 5654.80 lakhs. The net issue expenses are Rs 765.80 lakhs has been adjusted against securities premium.

**For and on behalf of Board of**  
**Unihealth Consultancy Limited**  
(Formerly Known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)

  
Akshay M Parmar  
Managing Director  
DIN:01533004  
Place : Mumbai  
Date: 08th November 2023



**UNIHEALTH CONSULTANCY LIMITED**  
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)  
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034  
CIN : U85100MH2010PLC200491

**STATEMENT OF UNAUDITED CONSOLIDATED ASSETS AND LIABILITIES AS ON SEPTEMBER 30, 2023**


(₹ in Lakhs)

	Particulars	As at 30 September, 2023	As at 31 March, 2023
		Unaudited	Audited
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Shareholders' Funds</b>		
	(a) Share capital	1,540.00	138.95
	(b) Reserves and surplus	6,520.32	2,612.83
		<b>8,060.32</b>	<b>2,751.78</b>
	(c) Minority Interest	(23.24)	(24.28)
<b>3</b>	<b>Non-current Liabilities</b>		
	(a) Long-term borrowings	2,784.20	3,569.54
	(b) Deferred Tax Liability (Net)	70.70	87.54
	(c) Other long-term liabilities	-	-
	(d) Long-term provisions	-	-
		<b>2,854.90</b>	<b>3,657.08</b>
<b>4</b>	<b>Current Liabilities</b>		
	(a) Short-term borrowings	81.72	357.13
	(b) Trade payables		
	(i) Total outstanding dues of micro enterprises and small enterprises	11.57	13.36
	(ii) Total outstanding dues to creditors other than micro enterprises and small enterprises	243.53	282.63
	(c) Other current liabilities	1,035.41	555.37
	(d) Short-term provisions	182.50	240.25
		<b>1,554.73</b>	<b>1,448.74</b>
	<b>TOTAL</b>	<b>12,446.71</b>	<b>7,833.32</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Property, plant and equipments and Intangible Asset		
	- Property, Plant and Equipment	2,841.19	2,945.66
	- Intangible assets	9.29	10.82
	- Goodwill on consolidation	751.46	751.46
	- Capital Work in Progress	-	-
	- Intangible Assets under development	-	-
	(b) Non-current investments	24.59	28.71
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	685.81	677.40
	(e) Other non-current assets	134.10	94.99
		<b>4,446.44</b>	<b>4,509.04</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Current investments	-	-
	(b) Inventories	167.97	211.24
	(c) Trade receivables	2,531.07	2,739.36
	(d) Cash and cash equivalents	5,112.65	195.38
	(e) Short-term loans and advances	188.58	178.30
	(f) Other current assets	-	-
		<b>8,000.27</b>	<b>3,324.28</b>
	<b>TOTAL</b>	<b>12,446.71</b>	<b>7,833.32</b>

**Notes:**

- Figures for the previous periods /year have been regrouped ,restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation.
- The company has issued and allotted 42,84,000 equity shares of Rs.10 each at a premium of Rs.122 per share on 21/09/2023 through initial public offer as per section 52 of companies act, 2013, aggregating to Rs 5654.80 lakhs. The net issue expenses are Rs 765.80 lakhs has been adjusted against securities premium.

For and on behalf of Board of  
Unihealth Consultancy Limited  
(Formerly Known as UNIHEALTH CONSULTANCY  
PRIVATE LIMITED)



Akshay M Parmar  
Managing Director  
DIN:01533004  
Place : Mumbai  
Date: 08th November 2023



**UNIHEALTH CONSULTANCY LIMITED**  
(Formerly known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)  
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034  
CIN : U85100MH2010PLC200491

**STATEMENT OF UNAUDITED CONSOLIDATED CASH FLOWS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2023**

(₹ in Lakhs)

Particulars	Half year ended September 30, 2023	Year ended March 31, 2023
	Unaudited	Audited
<b>A Cash flow from operating activities</b>		
Net profit before tax	516.81	927.78
<b>Adjustments for:</b>		
Depreciation/amortization	114.16	251.62
Loss/(Profit) on sale of Fixed Asset	-	(2.37)
Balances Written (Back)/Off	(0.16)	(8.27)
Finance Cost	153.49	412.13
Rent Receipts	(1.08)	(1.76)
Int on Income tax refund	-	(0.03)
Foregin Exchange (Gain)/Loss	(30.12)	(121.28)
Insurance Claim Received	-	(17.88)
Interest on FD & Loan given	(42.03)	(56.31)
<b>Operating profit before working capital changes</b>	<b>711.07</b>	<b>1,383.63</b>
<b>Changes in assets and liabilities:</b>		
(Increase) / decrease in Inventories	43.26	(31.51)
(Increase) / decrease in Trade Receivables	208.30	(920.10)
(Increase) / decrease in Short Term Loans and Advances	(10.28)	(1.77)
(Increase) / decrease in Current and Non Current Assets	(39.11)	(23.77)
Increase / (decrease) in Current and Non Current Liabilities	463.20	(254.43)
Increase / (decrease) in Long term and Short term Provisions	(2.04)	20.12
Increase / (decrease) in Trade Payables	(40.73)	122.94
<b>Cash (used in)/ generated from operating activities</b>	<b>1,333.67</b>	<b>295.11</b>
Income tax paid	(87.06)	(162.11)
<b>Net cash from/ (used in) from operating activities (A)</b>	<b>1,246.61</b>	<b>133.00</b>
<b>B Cash flow from Investing activities</b>		
(Increase) / decrease in long term loans & advances	(8.41)	(342.12)
Interest on FD & Loan given	42.03	56.31
Sale of Fixed Asset	-	22.07
Rent Receipts	1.08	1.76
Loss/(Profit) on sale of assets	-	2.37
Purchase of fixed assets	(13.92)	(231.97)
<b>Net cash from/ (used in) from investing activities (B)</b>	<b>20.78</b>	<b>(491.58)</b>
<b>C Cash flow from Financing activities</b>		
Proceeds/(Repayment) of Borrowings (Note 4)	(1,060.75)	625.37
Foreign Exchange Gain/(Loss)	30.12	121.28
Proceeds from Issuance of Share Capital	5654.88	-
Share Issue Expenses	(765.80)	-
Finance cost	(153.49)	(412.13)
<b>Net cash from / (used in) from financing activities (C)</b>	<b>3,704.96</b>	<b>334.52</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>4,972.35</b>	<b>(24.06)</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>195.38</b>	<b>234.97</b>
<b>Effect of Foreign Exchange Gain or Loss</b>	<b>(55.08)</b>	<b>(15.53)</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>5,112.65</b>	<b>195.38</b>

**Notes:**

- The cash flow statement has been prepared in accordance with the requirements of Accounting standard - 3 - Cash flow Statement issued in terms of section 133 of the Companies Act, 2013.

For and on behalf of Board of  
Unihealth Consultancy Limited  
(Formerly Known as UNIHEALTH CONSULTANCY PRIVATE LIMITED)

  
Akshay M Parmar  
Managing Director  
DIN:01533004  
Place : Mumbai  
Date: 08th November 2023

